WST

West Pharmaceutical Services, Inc.

HealthcareMedical Instruments & SuppliesNASDAQ

$322.81

+$6.82 (2.11%)today

Conviction

7/ 10

Fair Value$316.69

Upside-1.90%

Signal0

Market Cap$19.3B

52W Range$193.05–$322.34

Next EarningsApr 23

Conviction History

Conviction Changes

Mar 18, 2026, 5:05 PM6→7conviction-rescore

Premium Content

Upgrade to premium to see the full reasoning behind each conviction change.

Price History

FAIR VALUE ANALYSISMonte Carlo · 3,000 runs · 99% valid

Fair Value$92.54

Current Price$240.31

Upside / Down-61.5%

P(Undervalued)0.0%

P(20%+ Up)0.0%

P(15%+ Down)100.0%

Fair Value Distribution — percentile bands

0.0% of simulations place fair value above current price

WHAT IS PRICED IN

Revenue-Based Reverse DCF

28.8%/yr

±5.5% · revenue growth to justify current price

FCF-Based Reverse DCF

27.4%/yr

±3.3% · FCF growth to justify current price

THE GAP

Market pricing margin expansion or capex normalization

Premium Content

Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.

Bull Case

West Pharmaceutical Services drug delivery components; biologics/injectable volumes growing.

Bear Case

Pharma capex destocking; pricing pressure from hospital consolidation; high valuation.

Updated Apr 7

Research Feed

sec_10kMar 3

Conviction: unchanged

WST 2025 10-K: Strong Margin Expansion & GLP-1 Momentum

WST delivered solid 2025 results: 6.3% revenue growth, margin expansion +140bps to 35.9%, strong Proprietary segment (40.5% margin). GLP-1 tailwinds evident in self-injection devices. Restructuring on...